Impact of prior immunotherapy on paclitaxel/bevacizumab in advanced non-squamous non-small cell lung cancer

Immunotherapy is becoming essential in the management of advanced non-small cell lung cancer (NSCLC); however, the best treatment sequence remains to be determined. Some data suggest that immunotherapy prior to chemotherapy with paclitaxel/bevacizumab (PB) appears to be an interesting option. Here,...

Descripció completa

Dades bibliogràfiques

Autors principals:	Agathe Peyret, Clémentine Le Berrurier, Luc Heraudet, Tara Delon, Maéva Zysman, Mathieu Larroquette, Laura Leroy, Sophie Cousin, Charlotte Domblides
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2025-10-01
Col·lecció:	Frontiers in Oncology
Matèries:	NSCLC immunotherapy chemotherapy therapeutic sequence anti-angiogenic treatment
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1675386/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!